Alkermes plc
HealthcareNASDAQ:ALKS · NASDAQ Global Select
-$0.34 today
Vol 1.46M · Avg 2.34M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
13.3%
avg -3.6%
ROIC
10.6%
avg 0.0%
ROA
9.6%
avg -2.2%
Analysis
ROE is currently the strongest return metric at 13.3% versus its period average of -3.6%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Richard F. Pops | Chairman & Chief Executive Officer | $2.89M | — | 64 | $37,226.00 | 0.02% |
Craig C. Hopkinson | Executive Vice President of Research & Development and Chief Medical Officer | $1.42M | — | 57 | $77,389.00 | 0.05% |
Blair C. Jackson | Executive Vice President, Chief Risk Officer & Chief Operating Officer | $1.37M | — | 53 | $77,389.00 | 0.05% |
David Joseph Gaffin | Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary | $1.28M | — | 54 | $229,524.00 | 0.14% |
Christian Todd Nichols | Senior Vice President & Chief Commercial Officer | $1.06M | — | 56 | $109,769.00 | 0.07% |
Joshua Reed | Senior Vice President & Chief Financial Officer | $743,971.00 | — | 53 | $66,430.00 | 0.04% |
Tom Skoff | SVP & Chief Information Officer | — | — | — | — | — |
Sandra Coombs | Senior Vice President of Corporate Affairs & Investor Relations | — | — | — | — | — |
Declan O'Connor | Senior Vice President of Operations and Environment, Health & Safety | — | — | — | — | — |
Stephen Schiavo | Senior Vice President & Chief Human Resources Officer | — | — | — | — | — |
Thomas Harvey | Chief Information Officer & Senior Vice President of IT | — | — | — | — | — |
Samuel J. Parisi | Interim Principal Accounting Officer & Vice President of Finance | — | — | 51 | $7,717.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
22
$6.15M
Net Sentiment
$6.15M
Net selling
Most Active
Hopkinson Craig C.
12 transactions
1–10 of 22
Analysis
Insiders reported 0 buys worth $0.00 and 22 sells worth $6.15M over the last 12 months. That adds up to net selling of $6.15M. Hopkinson Craig C. was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +3.0% | +10.0% (15yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +3.0% over three years. Forward estimates point to Revenue at +10.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Arrowhead Pharmaceuticals, Inc.
NASDAQ:ARWR
$10.44B
TG Therapeutics, Inc.
NASDAQ:TGTX
$7.61B
Protagonist Therapeutics, Inc.
NASDAQ:PTGX
$7.08B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.03B
Vaxcyte, Inc.
NASDAQ:PCVX
$6.87B
Arcellx, Inc.
ACLX
$6.73B
PTC Therapeutics, Inc.
NASDAQ:PTCT
$6.22B
CRISPR Therapeutics AG
NASDAQ:CRSP
$4.81B
Akero Therapeutics, Inc.
AKRO
$4.50B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.64B
Who manages ALKS?
Alkermes plc (ALKS) lists 12 active executives. The top listed executive is Richard F. Pops, Chairman & Chief Executive Officer.
Are ALKS insiders buying or selling?
Recent insider activity shows net buying of $8.56M.
Explore More
Continue the stock analysis
Jump to another research area for this company.